Rapigen
Manufacturer and developer of in-vitro diagnostic kits and reagents, with expertise in rapid (point-of-care) diagnostics and molecular PCR-based diagnostics. Offers end-to-end activities from raw material design and assay development to high-volume manufacturing and global distribution, and supports OEM customization. Exports products to multiple countries and has documented national authorizations and export approvals.
Industries
Nr. of Employees
medium (51-250)
Rapigen
Headquarters / Rapid Diagnostics Division & 1st Factory: 161 Saneop-ro, 155 Beon-gil, Gwonseon-gu, Suwon-si, Gyeonggi-do, 16648, Republic of Korea
Products
Rapid diagnostic tests (RDTs)
Point-of-care rapid immunoassay tests, including COVID-19 related self-tests and other infectious disease RDTs.
Molecular diagnostic kits
PCR-based molecular diagnostic products and related reagents and consumables for laboratory and point-of-care use.
Veterinary diagnostic products
Diagnostic kits tailored for veterinary and animal health applications.
Rapid diagnostic tests (RDTs)
Point-of-care rapid immunoassay tests, including COVID-19 related self-tests and other infectious disease RDTs.
Molecular diagnostic kits
PCR-based molecular diagnostic products and related reagents and consumables for laboratory and point-of-care use.
Veterinary diagnostic products
Diagnostic kits tailored for veterinary and animal health applications.
Services
Custom manufacturing and private-label production of diagnostic kits and reagents tailored to partner specifications.
Contact center support for inquiries and regional sales/technical liaison (separate contact pages for USA and other countries).
Custom manufacturing and private-label production of diagnostic kits and reagents tailored to partner specifications.
Contact center support for inquiries and regional sales/technical liaison (separate contact pages for USA and other countries).
Expertise Areas
- In-vitro diagnostics
- Rapid diagnostic tests (point-of-care)
- Molecular diagnostics (PCR-based)
- Immunodiagnostics and reagent development
Key Technologies
- Lateral flow immunoassays
- Gold nanoparticle labeling for lateral flow assays
- PCR-based molecular assays
- Point-of-care cartridge systems
News & Updates
Company planned participation in MEDICA (Düsseldorf) to present medical technology and diagnostic products.
Company planned participation in ASTMH annual meeting to present and network on tropical medicine and diagnostics.
Received national market authorization from the Korean regulatory authority for a COVID-19 home/self-test product (first self-test to receive that authorization as stated on the site).
Completed delivery of 18 million malaria rapid diagnostic tests to a national ministry of health, executed via multiple chartered shipments.
Received export approval for a multi-detection CT/NG diagnostic product (export/manufacturing approval reported in news).
Company planned participation in MEDICA (Düsseldorf) to present medical technology and diagnostic products.
Company planned participation in ASTMH annual meeting to present and network on tropical medicine and diagnostics.
Received national market authorization from the Korean regulatory authority for a COVID-19 home/self-test product (first self-test to receive that authorization as stated on the site).
Completed delivery of 18 million malaria rapid diagnostic tests to a national ministry of health, executed via multiple chartered shipments.
Received export approval for a multi-detection CT/NG diagnostic product (export/manufacturing approval reported in news).